Download Full Text (551 KB)
- Febrile neutropenia (FN) affects over 80% of patients with hematologic cancer and 10% to 50% of patients with solid tumors
- National Comprehensive Cancer Network (NCCN) guidelines recommend empiric broad-spectrum monotherapy until the absolute neutrophil count (ANC) is over 500 cells/uL.
- Extended durations with broad-spectrum agents leads to increased risk of antibiotic resistance, toxicity and C. difficile infection.
- To evaluate antibiotic prescribing patterns for patients with FN to optimize antibiotic stewardship.
Antibiotic stewardship, Febrile neutropenia, Hematologic cancer
Pharmacy Administration, Policy and Regulation | Pharmacy and Pharmaceutical Sciences
Jensen, Kayla; Aubert, Patricia; Ward, Joy; and Wigton, Ann, "Evaluation of Antibiotic Use and Duration for Febrile Neutropenia" (2020). Pharmacy Posters. 8.